Regulatory Requirements for Clinical Trial Labeling
Labeling errors can lead to protocol deviations, dosing mistakes, and even patient harm. Regulatory bodies such as the CDSCO, USFDA, and EMA have well-defined expectations for investigational labels. Sponsors must ensure that all IPs are labeled accurately before release and that labels support the safe and blinded use of the product across sites.
Click to read the full article.